Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real-World Data

IF 3.3 4区医学 Q2 HEMATOLOGY

Hematological Oncology Pub Date : 2025-01-08 DOI:10.1002/hon.70024

Minna Harmanen, Mika Hujo, Reijo Sund, Marc Sorigue, Madiha Khan, Roosa Prusila, Tuula Klaavuniemi, Esa Kari, Esa Jantunen, Kaisa Sunela, Aino Rajamäki, Erika Alanne, Hanne Kuitunen, Juan-Manuel Sancho, Arja Jukkola, Aino Rönkä, Outi Kuittinen

引用次数: 0

Abstract

Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.

查看原文本刊更多论文

套细胞淋巴瘤的终生治疗轨迹：基于20年真实世界数据的模拟分析。

套细胞淋巴瘤是一种罕见的b细胞淋巴瘤，被认为是无法治愈的。近年来，套细胞淋巴瘤的治疗选择成倍增加，治疗的重点有望从传统的化学免疫治疗转向精准医学。然而，靶向治疗的高成本阻碍了这一发展。为了为未来评估新型和新兴MCL治疗的成本和收益提供基线，我们基于2000年至2020年间诊断和治疗的化疗免疫治疗时代患者的回顾性队列建立了终身治疗轨迹的预测模拟模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematological Oncology 医学-血液学

CiteScore

4.20

自引率

6.10%

发文量

147

审稿时长

>12 weeks

期刊介绍： Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged: -Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders -Diagnostic investigations, including imaging and laboratory assays -Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases -Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies -Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems. Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.